Posts

Anthropic Acquires Stealth AI Biotech Startup Coefficient Bio in $400M Stock Deal

on
Anthropic acquired stealth biotech AI startup Coefficient Bio in an all-stock deal valued at approximately $400 million. The deal was reported by The Information and confirmed by sources to TechCrunch, Fierce Biotech, and others; it has closed. Coefficient Bio, founded in 2025 (about 8 months ago), focused on using AI to enhance drug discovery, biological research, R&D planning, and regulatory strategy. Key founders include Nathan C. Frey, Samuel Stanton (ex-Genentech Prescient Design), Aris Theologis (CEO, ex-Evozyne), and Joyce Hong. The small team (6-10 people), backed by Dimension VC, will join Anthropic's health and life sciences team led by Eric Kauderer-Abrams. This acquisition supports Anthropic's expansion into healthcare, following launches like Claude for Life Sciences (October 2025) and Claude for Healthcare (January 2026). Sources:

AI-Designed Drug Candidate Targets Kappa-Opioid Receptor to Treat Opioid Addiction

on

Takeda Terminates Denali Partnership, Returns DNL593 Dementia Asset Amid Restructuring

on

Rules of Engagement: How G3BP2 Paves the Way to Rationalize Novel Degrons

on

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion to Expand Rare Disease Portfolio with VYKAT XR

on

Trump Imposes 100% Tariffs on Imported Patented Drugs with Key Exceptions

on

Novo Nordisk Launches Discounted Multi-Month Subscription Program for Wegovy via Telehealth Providers

on

FDA Ties Amgen's Tavneos to Eight Deaths and 76 Liver Injury Cases

on

Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

on

Biotech IPOs Rebound as AI Drives Drug Development Innovation

on

Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at AACR Annual Meeting

on

Biodexa Announces Partnership with Syngene to Manufacture MTX240 GMP Clinical Trial Supplies

on

Trump Announces Up to 100% Tariffs on Imported Patented Drugs

on